IceCure Medical Ltd. filings document the company’s status as a foreign private issuer and its disclosures around ProSense cryoablation technology, clinical and regulatory updates, commercial activity, governance and capital structure. Form 6-K reports furnish press releases on financial and operating results, FDA-related matters, medical-conference updates and clinical data for ProSense in tumor-destruction applications.
The filing record also includes proxy materials for shareholder voting, registration-statement references on Forms F-3 and S-8, ordinary-share voting information, executive and board changes, employment and indemnification arrangements, and litigation disclosure related to a prior private placement. These filings frame ICCM’s formal reporting around its medical-device business and public-company obligations.
IceCure Medical Ltd. (ICCM) is seeking shareholder approval for authority to effect one or more potential reverse share splits, each at a ratio of at least 5-for-1 and with a cumulative ratio no greater than 40-for-1, within 24 months after the November 19, 2026 meeting. The board would decide whether to proceed and select the ratio and effective date, subject to shareholder approval and applicable requirements.
The board says the proposal is intended to help support compliance with Nasdaq’s $1.00 minimum bid-price requirement. If a reverse split is implemented, authorized share capital would remain 2.5 billion ordinary shares, while issued and outstanding shares would be reduced proportionately; the company states that future share issuances may dilute existing shareholders. Shareholders of record on November 4, 2026 are eligible to vote.
On November 2, 2026, Eyal Shamir, IceCure Medical Ltd.'s Chief Executive Officer and director, reported an award of 404,901 restricted share units (RSUs), granted August 11, 2026. Twenty-five percent vest on August 11, 2027; the remaining 75% vest in twelve equal quarterly installments of 6.25% thereafter.
As of November 2, 2026, his direct holdings included 2,596 ordinary shares and 428,685 RSUs, of which 9,862 were vested and 418,823 remained unvested. The holdings were adjusted to reflect the issuer's 1-for-30 reverse share split effected June 4, 2026.
IceCure Medical Ltd. (ICCM) director Mayron Ron acquired 166,577 restricted share units (RSUs), granted August 11, 2026; all 166,577 vested immediately upon shareholder approval on November 2, 2026. His reported post-transaction holdings were 176,464 securities, comprising 333 ordinary shares and 176,131 RSUs as of November 2, 2026. The holdings were adjusted for the issuer’s 1-for-30 reverse share split effected June 4, 2026.
IceCure Medical Ltd. held its Annual and Special General Meeting of Shareholders on November 2, 2026. The meeting was initially adjourned because a quorum was not present at 5:00 p.m. Israel time. The adjourned meeting was held at 6:30 p.m., when a quorum was present, and shareholders voted upon and approved the agenda items described in the company’s proxy statement.
IceCure Medical Ltd. (ICCM) said its ProSense® breast cancer cryoablation system was featured in scientific presentations, research posters and physician workshops at the European Society of Breast Imaging’s 2026 meeting in Maastricht, Netherlands. Presentations reported 12-month objective response rates of 97.5% among 40 patients treated with cryoablation plus endocrine therapy and 91.7% among 24 patients treated with cryoablation alone.
Dr. Lucía Graña-López and Dr. Francesca Pugliese gave scientific presentations; Dr. Graña-López and Dr. Federica Di Naro led two workshops, each with nearly 70 participants. Posters were presented by Dr. Georgiana-Cristiana Camen and Dr. Pugliese. IceCure describes ProSense as FDA-cleared for local treatment of breast cancer in patients aged 70 years and older with biologically low-risk tumors ≤1.5 cm who receive adjuvant endocrine therapy, including patients not eligible for surgery. Chief Executive Officer Eyal Shamir commented on physician engagement at the meeting.
IceCure Medical Ltd. updated its November 2, 2026 shareholder-meeting materials after director Yang Huang said on October 4, 2026, that he would not seek re-election; he will serve until the meeting. The amended agenda removes items related to Mr. Huang. Shareholders of record at the close of business on October 5, 2026, may vote.
Shareholders will consider a proposed 404,901-RSU grant to CEO and director Eyal Shamir, with an annual value of approximately $1,328,075, and a proposed 230,577-RSU grant to Chairman Ron Mayron. Mayron’s award includes 166,577 RSUs after shareholder approval and 64,000 RSUs upon completion of a financing transaction generating at least $6.5 million in gross proceeds, provided the second grant’s annual value and dilution rate remain within the Compensation Policy framework. Both awards have a stated schedule of one-quarter vesting on the first grant anniversary and the remainder in 12 equal quarterly installments over three years. The financial statements discussion is not subject to a vote.
IceCure Medical Ltd. said the American Medical Association’s CPT Editorial Panel did not approve its request to replace the temporary CPT category III code for cryoablation of cancerous breast tumors with a permanent category I code. The panel determined the transition was premature after reviewing the application at its September 2026 meeting.
The existing temporary code remains in place, allowing facilities to be paid by CMS approximately $4,000 for the ProSense procedure facility fee. The decision does not affect IceCure’s ability to continue commercial activities under the existing reimbursement framework. The company may resubmit its request in June 2027.
IceCure Medical Ltd. is asking shareholders to vote at its November 2, 2026 annual and special meeting on auditor reappointment, a three-year reappointment of director Yang Huang until the 2029 annual meeting, and three equity-compensation grants. Discussion of the company’s 2025 audited financial statements is not a vote.
The proposed grants are 404,901 RSUs for CEO and director Eyal Shamir, 230,577 for Chairman Ron Mayron, and 60,000 for director Yang Huang. Mayron’s proposed grant includes 166,577 RSUs after shareholder approval and 64,000 upon completion of a company financing yielding at least $6.5 million in gross proceeds, subject to the Compensation Policy’s annual-value and dilution limits at grant. The board recommends “FOR” each voted proposal.
IceCure Medical Ltd. (ICCM) announced that China’s National Medical Products Administration (NMPA) has granted regulatory approval, as a Class III medical device, for its ProSense® cryoablation system and associated cryoprobes. This approval allows ProSense® to be marketed in China in line with the approved registration.
The company states that this is an important regulatory milestone that strengthens its global regulatory position and expands the markets in which ProSense® can be commercialized. ProSense® is already marketed for approved indications in the U.S., Europe and parts of Asia, with primary focus areas including breast, kidney, bone and lung cancer.
IceCure Medical Ltd. (ICCM) reported entering an exclusive distribution agreement with Scovas Medical for its ProSense® cryoablation systems in the Netherlands, covering breast cancer and interventional oncology. Scovas will act as exclusive distributor for an initial term with a view to negotiating a longer-term agreement, subject to the parties’ agreement.
The Netherlands is highlighted as a strategic market, as the independent multicenter randomized THERMAC trial, conducted there, has advanced to Phase III with a focus on cryoablation. Previously published THERMAC data reported that ProSense® achieved a 94% success rate, a 0% complication rate, and 100% treatment tolerance without the need for general anesthesia among evaluated thermal ablation techniques.